Biotechnology

Mirum Pharmaceuticals

Mirum Pharmaceuticals Launches $600M Convertible Senior Note Private Placement

Mirum Pharmaceuticals Issues $600 Million Convertible Senior Notes Offering

Mirum Pharmaceuticals released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 159.88 M (forecast USD 153.05 M), actual EPS USD -13.4299 (forecast USD -0.3655)

Mirum Pharmaceuticals Reports 43% Increase in Net Product Sales in Q1 and Raises Full-Year Sales Guidance

Mirum Pharmaceuticals reports Q1 financial loss

HC Wainwright Raises Target Price and Maintains Buy Rating on Mirum Pharmaceuticals

Mirum Pharmaceuticals' Drug Volixibat Shows Progress in Primary Sclerosing Cholangitis Study

Mirum Pharmaceuticals to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 148.2 M, EPS USD -0.3655

Mirum Pharmaceuticals Executives Sell Shares

Mirum Pharmaceuticals Completes Enrollment in LIVMARLI® Phase III Extension Study

Mirum Pharmaceuticals Completes AZURE-1 Trial Enrollment

Mirum Pharmaceuticals updates progress on chronic hepatitis delta virus treatment drug BreloVitug's Azure clinical project

Evercore ISI raises Mirum Pharmaceuticals price target to $126

Mirum Pharmaceuticals released FY2025 Q4 earnings on February 25 After-Market EST, actual revenue USD 148.93 M (forecast USD 141.78 M), actual EPS USD -0.123 (forecast USD 0.056)

Mirum Pharmaceuticals released FY2025 earnings on February 25 After-Market EST, actual revenue USD 521.31 M (forecast USD 515.52 M), actual EPS USD -0.47 (forecast USD -0.2663)

Mirum Pharmaceuticals Reports 2025 Sales Growth and Completes Bluejay Therapeutics Acquisition

Mirum Pharmaceuticals to Release FY2025 Q4 Earnings on February 25 After-Market EST, Forecast Revenue USD 141.78 M, EPS USD 0.0488

Mirum Pharmaceuticals Receives Health Canada Approval for LIVMARLI®

Mirum Pharmaceuticals Inc. CEO Reports Disposition of Common Stock

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TILE

MIRM

OKLO

TYRA

Top Wall Street analysts have initiated coverage on several companies with varying ratings. Oklo Inc (OKLO) received a Peer Perform rating, X-Energy Inc (XE) an Overweight rating with a $41 price target, Mirum Pharmaceuticals Inc (MIRM) an Outperform rating with a $145 target, Interface Inc (TILE) a Buy rating with a $36 target, and Tyra Biosciences Inc (TYRA) a Peer Perform rating.

benzinga_article

Interface

X-Energy

Oklo

Tyra Biosciences

This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Mirum Pharmaceuticals (MIRM) has seen a strong performance with a 31% stock increase this year, but recently experienced a pullback, closing at $102.19, down 8.3% in one day. Analysts estimate a fair value of $129.73, suggesting the stock is undervalued. The company has multiple late-stage pipeline catalysts that could drive future growth, but risks remain if key trials disappoint or pricing pressures arise.

Simplywall

Assessing Mirum Pharmaceuticals (MIRM) Valuation After A Strong Year And Recent Share Price Pullback

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News

StockTitan

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News

Earnings Watch

Mirum Pharmaceuticals | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 159

Mirum Pharmaceuticals(MIRM.US)

This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Assessing Mirum Pharmaceuticals (MIRM) Valuation After A Strong Year And Recent Share Price Pullback

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News

Mirum Pharmaceuticals | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 159